Multiple endocrine neoplasia type 2 (MEN2)
MEN2 · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Autosomal dominant RET proto-oncogene syndrome causing medullary thyroid carcinoma, phaeochromocytoma and (type 2A) hyperparathyroidism. Genotype-directed prophylactic thyroidectomy prevents medullary thyroid cancer death.
Red flags
- Undetected phaeochromocytoma before thyroid/parathyroid surgery
- Rising calcitonin (persistent/recurrent medullary carcinoma)
- Hypertensive crisis
- Distant metastatic medullary thyroid carcinoma
- Severe hypocalcaemia after thyroidectomy
Assessment
Differential diagnosis
- Sporadic medullary thyroid carcinoma
- MEN1
- Sporadic phaeochromocytoma
- Familial medullary thyroid carcinoma
- Neurofibromatosis-associated tumours
Investigations
- Calcitonin and carcinoembryonic antigen (medullary thyroid carcinoma)
- Plasma/urinary metanephrines before any surgery
- Calcium and PTH (type 2A)
- Neck ultrasound and functional imaging for staging
- Germline RET mutation testing and cascade screening
Management
- Confirm diagnosis with RET genetic testing and stratify by codon-specific risk
- Always exclude phaeochromocytoma before any surgery
- Offer risk-stratified prophylactic total thyroidectomy (timing by RET genotype)
- Resect established medullary thyroid carcinoma with appropriate nodal dissection
- Treat phaeochromocytoma with alpha-blockade then adrenalectomy before thyroid surgery
- Manage hyperparathyroidism (type 2A) when present
- Monitor calcitonin/CEA trends for persistent/recurrent disease
- Use RET-selective kinase inhibitors for advanced/progressive medullary thyroid carcinoma
- Cascade-test relatives and offer early intervention to gene carriers
- Provide lifelong surveillance and genetic counselling
Drugs & doses
Levothyroxine replacement after thyroidectomy
Alpha-blocker (phenoxybenzamine/doxazosin) before phaeochromocytoma surgery
Selpercatinib or pralsetinib (RET inhibitors) for advanced medullary thyroid carcinoma
Calcium/vitamin D for post-surgical hypoparathyroidism
Disposition
Manage in a specialist endocrine-surgical centre with genetics; prioritise phaeochromocytoma exclusion and arrange cascade family testing and lifelong follow-up.
Complications & pitfalls
- Metastatic medullary thyroid carcinoma
- Phaeochromocytoma crisis
- Post-thyroidectomy hypoparathyroidism/recurrent laryngeal nerve injury
- Recurrent hyperparathyroidism
- Treatment-related toxicity
Exam pearls
- Always exclude phaeochromocytoma before operating; adrenal surgery precedes thyroid surgery
- Prophylactic thyroidectomy timing is dictated by the specific RET codon
- Calcitonin and CEA trends track medullary thyroid carcinoma burden
- Highest-risk RET mutations warrant thyroidectomy in infancy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.